

- Epidural abscess  
  spinal, 863-864, 864f  
  subdural empyema with, 863
- Epigenetic control of gene expression, 6
- Epigenetics, 6
- Epilepsy, 1051-1063. *see also* Seizures.  
  activity restrictions in, 1051  
  benign Rolandic, 1054  
  classification of, 1051-1053  
  clinical manifestations of, 1052-1053  
  definition of, 1051-1052  
  diagnosis of, 1057-1058  
  differential diagnosis of, 1058, 1058t  
  epidemiology of, 1051-1052  
  etiology of, 1052f  
  generalized  
    idiopathic (primary), 1056, 1059  
    symptomatic, 1056-1057  
  genetic counseling and pregnancy in, 1061-1062  
  genetics of, 1052, 1054  
  history and examination of, 1057  
  nocturnal, 1051-1052  
  pathology of, 1052  
  posttraumatic, 1055  
  prognosis of, 1062-1063  
  psychosocial concerns in, 1062  
  seizure threshold in, 1051  
  surgery of, 1060  
  symptomatic seizures and, 1051  
  treatment of, 1058-1061
- Epinephrine, 650
- Episcleritis, inflammatory bowel disease with, 420
- Epistaxis, *vs.* hemoptysis, 186
- Eplerenone  
  for adrenal hyperplasia, 171  
  in hyperkalemia, 305
- Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF), 63
- Epoprostenol, for pulmonary hypertension, arterial, 164
- Epstein-Barr virus (EBV)  
  hemolytic anemia, 509  
  in oral disease, 936
- Epstein-Barr virus (EBV) infection  
  fever in, 843  
  infectious mononucleosis in, 843  
  mononucleosis syndrome in, 837
- Eptifibatid, 565
- Epworth Sleepiness Scale (ESS), 971, 971t
- Equilibrium potential for K<sup>+</sup>, 110
- ERCP. *see* Endoscopic retrograde cholangiopancreatography (ERCP).
- Erectile dysfunction, 716-719  
  alprostadil intraurethral drug therapy for, 718  
  cardiovascular disease of, 717  
  causes of, 717-719  
  in diabetes mellitus, 717-718  
  diabetic neuropathy and, 671  
  in endocrine disorders, 717-718  
  intracavernosal injection therapy for, 719  
  medical and surgical therapies for, 718  
  medication-induced, 718  
  neurogenic, 717  
  oral phosphodiesterase type 5 inhibitors for, 718  
  penile prosthesis for, 719
- Erectile dysfunction (Continued)  
  prevalence of, 716  
  vacuum constriction devices for, 719
- Erection, penile, mechanism of, 716-717
- Erlotinib, 590t  
  for lung cancer, 270, 597
- Erysipelas, 884, 885f
- Erysipelothrix rhusiopathiae*, skin and soft tissue infection from, 886
- Erythema nodosum, in inflammatory bowel disease, 420
- Erythrocyte, hemolysis from causes extrinsic to, 509
- Erythrocyte sedimentation rate  
  in rheumatic disease, 769  
  in rheumatoid arthritis, 773
- Erythrocytosis, causes of, 490t
- Erythroid cells, 479  
  in myelodysplastic syndrome, 485
- Erythromycin  
  for gastroparesis, 415  
  mechanism of action, 4
- Erythropoiesis-stimulating agents (ESAs), 288
- Erythropoietin (EPO), 288  
  in acute kidney injury, 361.e1t  
  chronic kidney disease and, 365-366  
  exogenous, for anemia, 480-481  
  polycythemia vera and, 490  
  recombinant, chronic administration of, 486
- Escherichia coli*, 952  
  diarrhea from, 901-902  
  enterotoxigenic, 899, 900t, 901  
  hemolytic-uremic syndrome and, 325, 349, 570  
  P-fimbriated, 910  
  Shiga toxin-producing, 899, 901-902  
  in urinary tract infections, 910
- Esomeprazole  
  for peptic ulcer disease, 407-408  
  for stress bleeding prophylaxis, 412
- Esophageal cancer, 598
- Esophageal disorders, 396-401  
  Barrett's esophagus, 398, 398.e1f  
  dysphagia, 398-399  
    imaging studies in, 393  
  eosinophilic esophagitis, 401  
  gastroesophageal reflux. *see* Gastroesophageal reflux disease (GERD)  
  in HIV-infected patients, 936  
  infections, 401  
  motility disorders, 399-401  
  motor disorders, 400t  
  rings and webs, 400-401  
  symptoms of, 396-397
- Esophageal sphincter, lower, 402  
  agents affecting, 402f
- Esophagitis, eosinophilic, 401
- Esophagogastroduodenoscopy, 389-390, 390f  
  for gastric cancer, 599
- Esophagus, normal function of, 396
- Essential thrombocythemia, 491-492  
  diagnostic criteria for, 491t
- Essential tremor, 1019, 1019t
- Estrogen  
  menstrual cycle and, 698  
  osteoarthritis and, 805
- Estrogen (Continued)  
  therapy, for osteoporosis prevention and treatment, 762t
- Estrogen agonists-antagonists, 763
- Estrogen deficiency, osteoporosis and, 757-758
- Estrogen receptors, in breast cancer, 6
- Et tardus, 76-77
- Etanercept, 12, 778-779  
  for rheumatoid arthritis, 774t
- Ethanol, hypoglycemia from, 672
- Ethosuximide, 1059, 1060t
- Ethylene glycol poisoning, 309
- Eustachian tubes, 871, 871f
- Euthyroid sick syndrome, 638-639
- Evans' syndrome, 551
- Event recorder, 42
- Everolimus, 590t
- Evoked potentials (EPs), 963  
  in multiple sclerosis, 1070
- Ewing's sarcoma, 616
- Excessive daytime sleepiness (EDS), disorders of, 971
- Exenatide, for type 2 diabetes, 666, 666t
- Exercise  
  for coronary artery disease, 94  
  in fibromyalgia syndrome, 812  
  for hyperlipidemia, 693  
  for obesity, 678-679  
  for osteoporosis prevention, 761  
  in peripheral arterial disease, 160  
  in rheumatoid arthritis, 773  
  in type 1 diabetes, 663  
  in type 2 diabetes, 667
- Exercise stress testing, for coronary artery disease, 91, 93f
- Exercise tolerance, preoperative, 273
- Exhaled breath, analysis of, 203
- Existential pain, 1120
- Extensively drug-resistant TB (XDR-TB), 258
- External beam radiation, for brain tumors, 1066
- External counterpulsation, in angina pectoris, 97
- External event monitors, 112
- Extracellular fluid (ECF)  
  calcium homeostasis and, 732-735, 732f  
  magnesium homeostasis and, 739, 740f  
  volume, 299
- Extracorporeal membrane oxygenation (ECMO), 149, 150f
- Extramedullary hematopoiesis, 478  
  in primary myelofibrosis, 492
- Extrapneumonic necrosis, 432
- Extrarenal potassium losses, 303
- Eye, cholesterol embolization to, 346
- Eye movements  
  evaluation of, 1004-1005, 1005f, 1005t  
  ophthalmoplegia, 1004-1005  
    causes of, 1005t  
  reflex, in coma, 967-968
- F**
- Fabry's disease, 327-328, 327f
- Facioscapulohumeral muscular dystrophy, 1093
- Factitious disorder, 989
- Factor inhibitors, in congenital factor deficiencies, 560
- Factor V Cambridge mutation, 566